Pharmacopeia Inc

Pharmacopeia — Pharmacopeia Drug Discovery — BIO 2006

12 slides from Pharmacopeia's conference presentation, Apr 12, 2006

  1. Slide 1: BIO 2006 Chicago

    Link to searchable text of slide shown above

  2. Slide 2: Forward-Looking Statements

    Link to searchable text of slide shown above

  3. Slide 3: Pharmacopeia's Strategy

    Pharmacopeia’s Strate >) DARA Selected Indications Pharmacopei, Lead Lead Preclinical Phase: Discovery 4 Optimization 4 Development Former business Partner Partner Retain candidates at least to clinical validation with the option to continue alone to NDA for selected indications or partner for Ph Il

  4. Slide 4: Last Months Highlights

    e Last 12 Months Expanded product portfolio — 12 compounds in development including 1 from Pharmacopeia Advanced internal program to preclinical development — Licensed in dual acting receptor (AT ,/ET,) antagonist (DARA) Established strategic alliance — Entered enabling collaboration with GSK Achiev

  5. Slide 5: GlaxoSmithKline Partnership

    ros GlaxoSmithKline Partner. Announced March 30", 2006 Driven by GSK (CEEDO) desire to access unique platform Non-dilutive financing - $15 million * Solid milestone payments — up to $83 million per program * Double-digit royalties — up to mid-teen percent * Strong global partner for development and

  6. Slide 6: Internal Portfolio

    Internal Portfolio Pharmecopea Robust Growing Internal Pipeline Predinical Optimization Development Nour} PORGEHO Cariversler Phemiecopale > Pee08504 er Phamacopeia aKa —_—_> PSS75179 Rreumaoid/MS Fhamacopeia oRt ——> PS246518 Parkinsons. Pharmacopeia ‘cesivanetgs — PS388023 Angiogeness © Pharmacopei

  7. Slide 7: DARA — Compelling Business Opportunity

    DARA — Compelling Business OpportunityramacoferY Announced March 315, 2006 Dual Acting Angiotensin (AT,) and Endothelin (ET,) Receptor Antagonist (DARA) * Combines the properties of two marketed cardiovascular product classes in a single molecule — first-in-class * Strong preclinical and clinical da

  8. Slide 8: Partnered Programs and Royalty Interests

    lan) Pharmacopeia dinical ESPEN Optica Developrent 1 7 PeeADtas Meumatad— BidO Myers a a a SDE AatmaAleny axe ber eae —————E pesie cop ~SCing a ee Peees760 oncology Ee PeRBtIe® tonanmation Baten to —— > Perea ONS ramon PEGE! Onclogy het a rs PeeTe2e8 nanan cebnene eesti8 Intonation Sein = > PeBISTIS

  9. Slide 9: Financial Summary

    Financial Summary Pha ¢ Financial Data for the 3 Months Ended December 31, 2005 — $5.6 million in net revenue — $3.1 million in net loss ¢ Financial Data for the 12 Months Ended December 31, 2005 — $20.4 million in net revenue — $17.1 million in net loss * Cash, Cash Equivalents and Marketable Secur

  10. Slide 10: Stock Information

    Stock Inf Pharmacofeta + Stock Exchange: NASDAQ + Stock Symbol: PCOP + Shares Outstanding (3/10/2006): 15.2 million + 52- Week Range: $3.03 - $6.31 + Daily Trading Volume (4/3/2006)*: 76,000 shares + Market Capitalization (4/3/2006): ~ $80 million + Enterprise Value™: ~ $50 million “Trailing 3-month

  11. Slide 11: Near Term Milestones

    Near Term Milestone Pharm * Within 12 Months — Two internal candidates in pre-clinical development — One or more partnered programs in clinical Phase II — Strategic partnership with significant retained rights — Core clinical-regulatory capability added — Year end cash and short term investments of

  12. Slide 12: Link to searchable text of slide shown above

    Link to searchable text of slide shown above Searchable text section of graphics shown above [LOGO] [GRAPHIC] [LOGO] • BIO 2006 Chicago • April 12 th , 2006 • Leslie J. Browne, Ph.D. • President & CEO [LOGO] Forward-Looking Statements This presentation, and oral statements made with respect to infor

Pharmacopeia Drug Discovery — BIO 2006 on 6ix